Pomegra
Kodiak Sciences' DAYBREAK Phase 3 trial for Zenkuda hit every primary endpoint in wet AMD, sending KOD surging ~150% and triggering a massive short squeeze.
- Zenkuda and KSI-501 both met DAYBREAK's primary endpoint of non-inferiority vs. aflibercept in visual acuity at one year, with a p-value of 0.0007.
- KOD shares surged from the low $30s to approximately $87.71, adding roughly $3 billion in market cap in a single session.
- Short interest of 18.1% of float and 18.4 days to cover amplified the move into a full short squeeze.
Lead
Kodiak Sciences (NASDAQ: KOD) stock surged approximately 145% on Monday, September 28, 2026, after the company's pivotal Phase 3 DAYBREAK study reported that both Zenkuda (tarcocimab tedromer) and tabirafusp-ted met their primary endpoints in patients with treatment-naive wet age-related macular degeneration. Shares opened near the low $30s and closed at roughly $87.71, adding close to $3 billion in market capitalization in one of the largest single-session biotech moves of 2026.
What Did DAYBREAK Prove?
Both investigational agents demonstrated non-inferiority to aflibercept in best-corrected visual acuity gains at one year, achieving a p-value of 0.0007 - a statistically decisive margin. The approximately 690-patient study used an AI-driven retreatment protocol allowing dosing intervals ranging from every one month to every six months. Under strict treat-to-dry criteria, 54% of Zenkuda patients achieved a six-month dosing interval. The drug's intraocular inflammation rate measured 0%, compared with 0.9% for aflibercept, and its cataract adverse event rate came in at 0.5% versus 0.9% for the comparator arm.
Why Did the Short Squeeze Amplify the Move?
KOD carried short interest of 18.1% of its float - approximately 10.8 million shares - as of the August 31 settlement date, with 18.4 days to cover. Short positions had built aggressively, rising 182.6% since September 2025, as investors positioned against a company with no approved products and a history of clinical setbacks. When DAYBREAK cleared every primary measure, those shorts were forced to cover into thin liquidity, creating a cascading short squeeze that drove the stock far beyond what the data alone might have implied.
What Is Zenkuda and How Does It Work?
Zenkuda is built on Kodiak's proprietary Antibody Biopolymer Conjugate (ABC) platform, which links an anti-VEGF antibody to a biopolymer engineered to extend drug retention inside the eye and sustain therapeutic effect. Companion asset KSI-501 (tabirafusp-ted) adds a bispecific dimension by simultaneously targeting both VEGF and IL-6, addressing two inflammatory pathways. The durability profile - the majority of patients maintaining six-month dosing intervals - forms the central commercial argument against current standard-of-care regimens, which often require injections every four to eight weeks and impose a significant patient burden.
Regulatory Timeline
Kodiak plans to submit a multi-indication biologics license application for Zenkuda in the fourth quarter of 2026. The filing will consolidate data from five Phase 3 studies spanning wet AMD, diabetic retinopathy, and retinal vein occlusion - a broad dossier designed to support multiple label indications from a single regulatory submission.
Outlook
Kodiak advances from development-stage biotech to near-commercial status with a Q4 2026 BLA submission on the horizon. The DAYBREAK data establishes Zenkuda's non-inferiority on efficacy, a cleaner safety profile, and a durability advantage that directly addresses the largest unmet need in wet age-related macular degeneration management - reducing the injection burden for millions of patients. The near-term pivot moves to the FDA review clock, manufacturing readiness, and commercial infrastructure build-out in a market currently dominated by Regeneron's Eylea and Novartis' Beovu.
